FreeOx has developed the first cerebroprotective therapy designed to preserve the brain during acute ischemic stroke. It is the key piece in stroke treatment, as it focuses on microcirculation and sol...
Read moreOryzon Genomics today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of iadademstat for cancer therapy...
Read moreNanoligent is a company whose goal is to develop new anticancer drugs specifically targeting aggressive tumors, using a pioneering technological platform based on protein–drug nanoconjugates. The co...
Read moreThe Ophthalmology Department of Hospital de Sant Pau, together with the Ophthalmology Research Group of the Sant Pau Research Institute (IR Sant Pau), has recently participated in an international cli...
Read moreIn biologics manufacturing, upstream production often captures much of the spotlight. Fermentation, cell culture and expression systems are frequently discussed as the heart of drug development. Yet, ...
Read moreOna Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
Read moreLa Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) ha anunciado la ampliación de su procedimiento de evaluación acelerada para ensayos clínicos en fases tempranas, una medida que c...
Read moreEl equipo médico oncológico de Pivotal, con amplia experiencia en estudios de fase inicial y redacción médica, asumió el reto de acelerar el desarrollo del protocolo y garantizar un inicio regula...
Read moreNanoligent, a spin-off from the Institut de Recerca Sant Pau (IR Sant Pau) and the Universitat Autnoma de Barcelona (UAB), has closed a €12 million funding round led by Inveready to advance the deve...
Read moreAlthough operating under GMP standards is time-consuming and resource-intensive compared to working in a research setting, it is necessary for patient safety. These legally enforced GMP regulations re...
Read moreUn estudio del Centro Nacional de Investigaciones Oncológicas (CNIO) ayuda a entender cómo funcionan los nuevos fármacos que bloquean el oncogén KRAS, mutado en un alto porcentaje de cánceres de ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U...
Read more